NASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $3.22 +0.20 (+6.62%) Closing price 04:00 PM EasternExtended Trading$3.22 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About biote Stock (NASDAQ:BTMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get biote alerts:Sign Up Key Stats Today's Range$3.06▼$3.3350-Day Range$2.82▼$4.5552-Week Range$2.76▼$6.98Volume213,331 shsAverage Volume173,200 shsMarket Capitalization$159.20 millionP/E Ratio3.58Dividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company Overview biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas. Read More biote Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreBTMD MarketRank™: biote scored higher than 46% of companies evaluated by MarketBeat, and ranked 625th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus Ratingbiote has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst Coveragebiote has only been the subject of 1 research reports in the past 90 days.Read more about biote's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-28.00% Earnings GrowthEarnings for biote are expected to decrease by -28.00% in the coming year, from $0.75 to $0.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 3.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.37.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 3.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.89. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.90% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in biote has recently increased by 0.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.90% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in biote has recently increased by 0.10%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for BTMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added biote to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, biote insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address BTMD Stock News Headlinesbiote Corp. (BTMD) - Yahoo FinanceAugust 12, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for biote FY2025 EarningsAugust 12, 2025 | americanbankingnews.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.August 22 at 2:00 AM | Brownstone Research (Ad)biote (NASDAQ:BTMD) Stock Rating Lowered by Wall Street ZenAugust 11, 2025 | americanbankingnews.combiote Corp. (NASDAQ:BTMD) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comB. Riley Securities Downgrades biote (BTMD)August 8, 2025 | msn.combiote Corp. (BTMD) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comBiote Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | businesswire.comSee More Headlines BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $6.18 at the beginning of the year. Since then, BTMD stock has decreased by 47.7% and is now trading at $3.2350. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) released its earnings results on Wednesday, August, 6th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. The business had revenue of $48.86 million for the quarter, compared to analysts' expectations of $49.52 million. biote had a net margin of 15.73% and a negative trailing twelve-month return on equity of 21.00%. Read the conference call transcript. Who are biote's major shareholders? Top institutional shareholders of biote include Bandera Partners LLC (4.17%), Acadian Asset Management LLC (1.25%), Geode Capital Management LLC (1.13%) and Hillsdale Investment Management Inc. (0.77%). Insiders that own company stock include Guines Llc, Roystone Capital Management Lp, Stephen Mark Cone, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of biote own? Based on aggregate information from My MarketBeat watchlists, some other companies that biote investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings8/06/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Price Target for biote$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+98.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio3.36 Forward P/E Ratio4.03 P/E GrowthN/ANet Income$3.16 million Net Margins15.73% Pretax Margin19.17% Return on Equity-21.00% Return on Assets18.26% Debt Debt-to-Equity RatioN/A Current Ratio0.98 Quick Ratio0.74 Sales & Book Value Annual Sales$197.19 million Price / Sales0.76 Cash Flow$0.78 per share Price / Cash Flow3.88 Book Value($1.59) per share Price / Book-1.90Miscellaneous Outstanding Shares49,440,000Free Float37,574,000Market Cap$149.31 million OptionableNot Optionable Beta1.21 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:BTMD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.